Authorization

Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congressa??

- Interim analysis of B-Clear clinical study of bepirovirsen demonstrated end-of-treatment virologic response (VR) in patients with chronic hepatitis B - Phase 3 clinical study evaluating bepirovirsen as a monotherapy is anticipated to start in the first half of 2023- GSK to explore potential combination treatments to further reduce the global burden of chronic hepatitis BCARLSBAD, Calif., June 25, 2022 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), today announced that GSK presented positive results from an interim analysis of the Phase 2b B-Clear clinical study of bepirovirsen (formerly IONIS-HBVRx), an investigational antisense medicine for the treatment of patients with chronic hepatitis B virus (CHB).
Ionis announces presentation of positive Phase 2b data for chronic hepatitis B treatment at the EASL International Liver Congressa??
See also:
Leave a comment
News
  • Latest
  • Read
  • Commented
Calendar Content
«    Август 2022    »
ПнВтСрЧтПтСбВс
1234567
891011121314
15161718192021
22232425262728
293031